Evidence map›Paper›PMID 21596621›Full record

Trial reportThe Lancet. Oncology2011

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

Willem van Gijn, Corrie A M Marijnen, Iris D Nagtegaal, Elma Meershoek-Klein Kranenbarg, Hein Putter, Theo Wiggers, Harm J T Rutten, Lars Påhlman, Bengt Glimelius, Cornelis J H van de Velde and 1 more

12 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 12 registered trials, which are not on this map. Cited by 805 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
805citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01437514 phase2 / phase3terminatednot on this map

the Effect of the Preoperative Short-course Radiotherapy for the cT3/cN+ Mid-lower Rectal Cancer: a Prospective Randomized Study

TypeinterventionalSponsorWest China HospitalRan2011 to 2020Enrolled410ConditionsRectal NeoplasmsArmspreoperative short-course radiotherapy
NCT02498353 naunknown statusnot on this mapstarted 2015, after this paper: background citation

Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer

TypeinterventionalSponsorZhongnan HospitalRan2015 to 2020Enrolled100ConditionsRectal CancerArmspreoperative short-course radiotherapy with local boost, preoperative short-course radiotherapy without local boost, TME surgery
NCT02843191 phase3active not recruitingnot on this mapstarted 2016, after this paper: background citation

KCSP Trial of CONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After NeoadjUvant Concurrent ChemoraDiothErapy: a Multicenter, Randomized Controlled Trial (KONCLUDE)

TypeinterventionalSponsorKyung Hee University Hospital at GangdongRan2016 to 2026Enrolled358ConditionsRectal CancerArmsChemotherapy
NCT03001362 narecruitingnot on this mapstarted 2015, after this paper: background citation

Radical External Beam Chemoradiation in Patients With Rectal Cancer: a "Wait-and-see" Approach

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2015 to 2026Enrolled48ConditionsColorectal CarcinomaArmsRadical external beam radiotherapy
NCT03038256 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial

TypeinterventionalSponsorPeking University People's HospitalRan2018 to 2025Enrolled244ConditionsRectal Cancer, Pathological Complete Response, Disease Free SurvivalArmsconcurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX
NCT03351959 unknown statusnot on this mapstarted 2018, after this paper: background citation

Complete Pathologic Response Rectal Cancers EYSAC.1 Study

TypeobservationalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2018 to 2018Enrolled1,000ConditionsRectal CancerArmsneo-adjuvant treatment
NCT04103567 narecruitingnot on this mapstarted 2020, after this paper: background citation

Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2020 to 2030Enrolled220ConditionsRectal CancerArmsBiological collection
NCT04927897 recruitingnot on this mapstarted 2022, after this paper: background citation

DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer

TypeobservationalSponsorMaastricht Radiation OncologyRan2022 to 2027Enrolled50ConditionsRectal CancerArmsUltrasound, Rectoscopy, Scan, e.g. CT (resection specimen)
NCT06114420 unknown statusnot on this mapstarted 2023, after this paper: background citation

Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer

TypeobservationalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2023 to 2025Enrolled500ConditionsLocally Recurrent Colorectal CancerArmssalvage surgery
NCT06246344 suspendednot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled, Phase III Trial

TypeobservationalSponsorShandong Cancer Hospital and InstituteRan2023 to 2028Enrolled128ConditionsRectal CancerArmsAdaptive Boost Radiotherapy, Long course non-ART radiotherapy, Concurrent chemotherapy, Consolidation Chemotherapy, Total mesorectal excision (TME) surgery
NCT06991465 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Organ Preservation in Rectal Adenocarcinoma Using Hypofractionated Pelvic Radiotherapy (Hypo-OPRA): A Phase II Clinical Trial

TypeinterventionalSponsorNeil KopekRan2023 to 2029Enrolled35ConditionsColorectal CarcinomaArmsRadiation Therapy, FOLFOX regimen, Capecitabine
NCT07194616 narecruitingnot on this mapstarted 2025, after this paper: background citation

Impact of Neoadjuvant Chemoradiotherapy Versus Surgery Alone on Circulating Tumor Cells in Patients With Stage II-III Rectal Cancer and Negative Circumferential Resection Margin: a Multicenter Randomized Clinical Trial

TypeinterventionalSponsorUniversity Hospital OstravaRan2025 to 2028Enrolled120ConditionsRectal Cancer PatientsArmsPrimary Surgery, Neoadjuvant radiochemotherapy and surgery
3 · Its place in the literature

Who cites it

805 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

745 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Willem van GijnLeiden University Medical Centre, Leiden, The Netherlands.
Corrie A M Marijnen
Iris D Nagtegaal
Elma Meershoek-Klein Kranenbarg
Hein Putter
Theo Wiggers
Harm J T Rutten
Lars Påhlman
Bengt Glimelius
Cornelis J H van de Velde
Dutch Colorectal Cancer Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe TME trial investigated the value of preoperative short-term radiotherapy in combination with total mesorectal excision (TME). Long-term results are reported after a median follow-up of 12 years.

methodsBetween Jan 12, 1996, and Dec 31, 1999, 1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 × 5 Gy radiotherapy or TME alone (ratio 1:1). Randomisation was based on permuted blocks of six with stratification according to centre and expected type of surgery. The primary endpoint was local recurrence, analysed for all eligible patients who underwent a macroscopically complete local resection.

findings10-year cumulative incidence of local recurrence was 5% in the group assigned to radiotherapy and surgery and 11% in the surgery-alone group (p<0·0001). The effect of radiotherapy became stronger as the distance from the anal verge increased. However, when patients with a positive circumferential resection margin were excluded, the relation between distance from the anal verge and the effect of radiotherapy disappeared. Patients assigned to radiotherapy had a lower overall recurrence and when operated with a negative circumferential resection margin, cancer-specific survival was higher. Overall survival did not differ between groups. For patients with TNM stage III cancer with a negative circumferential resection margin, 10-year survival was 50% in the preoperative radiotherapy group versus 40% in the surgery-alone group (p=0·032).

interpretationFor all eligible patients, preoperative short-term radiotherapy reduced 10-year local recurrence by more than 50% relative to surgery alone without an overall survival benefit. For patients with a negative resection margin, the effect of radiotherapy was irrespective of the distance from the anal verge and led to an improved cancer-specific survival, which was nullified by an increase in other causes of death, resulting in an equal overall survival. Nevertheless, preoperative short-term radiotherapy significantly improved 10-year survival in patients with a negative circumferential margin and TNM stage III. Future staging techniques should offer possibilities to select patient groups for which the balance between benefits and side-effects will result in sufficiently large gains.

fundingThe Dutch Cancer Society, the Dutch National Health Council, and the Swedish Cancer Society.

Indexed as

AdultAgedAged, 80 and overCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRectal NeoplasmsRectum

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 6 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.